A Phase 1b/2 Study of Vorasidenib and Temozolomide in IDH-mutant Glioma

Study Description

A Study of an Experimental Drug Combination for the Treatment of IDH-mutant Brain Tumors

Study Details

Registry ID:

NCT06478212

Conditions:

IDH1-mutant Glioma, IDH2-mutant Glioma

Phase:

Phase 1,Phase 2

Target Enrollment:

51 participants

Start Date:

January 22, 2025

Healthy Volunteers:

No

Study Locations (28 sites)

• Hospital 12 de Octubre
  MadridSpain, Spain
• H. Valle de Hebron
  BarcelonaSpain, Spain
• IUCT-Oncopole Institut Universitaire du Cancer
  ToulouseFrance, France
• Ospedale Molinette - Centro Oncologico Ematologico
  TurinItaly, Italy
• Hôpital Pierre Wertheimer
  LyonFrance, France
• Instituto Clinico Humanitas IRCCS
  Rozzano, MilanItaly, Italy
• IOV - Ospedale Busonera
  PaduaItaly, Italy
• The Tel Aviv Sourasky Medical Center (TASMC) (Ichilov Hospital)
  Tel AvivIsrael, Israel
• Hôpital Pitié-Salpêtrière
  ParisFrance, France
• Universitätsklinikum Heidelberg
  HeidelbergGermany, Germany
• Medizinische Fakultät Mannheim, Universität Heidelberg
  MannheimGermany, Germany
• Universitätsklinikum Regensburg
  RegensburgGermany, Germany
• Medical University of Vienna - AKH
  ViennaAustria, Austria
• The Royal Marsden in Sutton
  SuttonUnited Kingdom, United Kingdom
• Erasmus MC
  RotterdamNetherlands, Netherlands
• Christie Hospital
  ManchesterUnited Kingdom, United Kingdom
• Dana Farber Cancer Institute
  Boston, MassachusettsUnited States, United States
• University of Miami
  Miami, FloridaUnited States, United States
• Memorial Sloan Kettering Cancer Center
  New York, New YorkUnited States, United States
• Duke University Medical Center
  Durham, North CarolinaUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• Beijing Tiantan Hospital, Capital Medical University
  BeijingChina, China
• University of California Los Angeles
  Los Angeles, CaliforniaUnited States, United States
• Huashan Hospital, Fudan University
  ShanghaiChina, China
• Kumamoto University Hospital
  KumamotoJapan, Japan
• Kyoto University Hospital
  KyotoJapan, Japan
• Nagoya University Hospital
  NagoyaJapan, Japan
• National Cancer Center Hospital
  TokyoJapan, Japan

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →